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Poster Session II 1275,10-methylenetetrahydrofolate reductase (MTHFR) is a central
regulatory enzyme in folate metabolism. A common functional
polymorphism of the MTHFR gene occurs at C677T. The
677TT genotype produces an enzyme with only 30% of the activity
of the wild-type (677CC) enzyme. The MTHFR polymorphism has
been shown to affect the sensitivity of patients to folate-based drugs
such as methotrexate (MTX) that is used for GVHD prophylaxis
following allogeneic hematopoietic stem cell transplantation
(HSCT). To assess the significance of C677T genotypes in
HSCT using MTX as a GVHD prophylaxis, we analyzed DNA
from159 patients with a hematological disease and theirHLA-iden-
tical sibling donors using PCR-RFLP method. The frequencies of
CC, CT and TT genotypes in the patients were 35%, 52% and
13%, respectively, and in the donors were 30%, 62% and 8%, re-
spectively. There was no significant difference in the distribution
patterns of the C677T genotypes between patients and donors (P
5 0.19). Multivariate analysis revealed a significantly lower inci-
dence of grade I-IV acute GVHD in patients with the 677TT geno-
type (relative risk, 0.35; 95% confidence interval, 0.13–0.95; P 5
0.040) and a non-malignant disease (0.22; 0.05–0.89; 0.034). There
was a significant association between a lower incidence of grade II-
IV acute GVHD and the use of bone marrow for transplantation
(0.32; 0.11–0.91; 0.032). There was no association between the in-
cidence of acute GVHD and the donor C677T genotypes. We an-
alyzed the incidence of acute GVHD in relation to the MTHFR
genotype using the Kaplan-Meier method. The incidence of grade
I-IV acute GVHD in the patients with 677TT genotype was signif-
icantly lower than in those with 677CC/CT genotype (19% versus
45%, P 5 0.035). There was a trend for a lower incidence of grade
II-IV acute GVHD in patients with 677TT genotype compared
with 677CC/CT genotype (5% versus 24%, P 5 0.077). The
C677T genotypes in the patient or donor were not associated
with the treatment-related mortality, relapse rate, relapse-free sur-
vival and overall survival. These results suggest that greater immu-
nosuppression by MTX due to low MTHFR enzyme activity
decreases the risk of acute GVHD in recipients of allogeneic
HSCT. Further studies are needed to confirm that the MTHFR
C677T polymorphism can predict the outcome of HSCT using
prophylactic MTX to prevent GVHD.346
HOMEOSTATIC AND INFLAMMATORY PROCESSES CONTRIBUTE TO EL-
EVATED PLASMA LEVELS OF B CELL ACTIVATING FACTOR (BAFF) IN
CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
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Rader, C., Cowen, E., Pavletic, S., Gress, R.E. National Cancer Institute,
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BAFF, a non-redundant cytokine produced by myeloid cells,
plays a critical role in the normal homeostatic maintenance, activa-
tion and function of B cells. Elevated circulating levels of BAFF,
however, have been observed in systemic autoimmune disorders
and, in murine models, have been linked to a failure to delete
auto-reactive B cells. We similarly observed elevated plasma
BAFF levels in 77 patients in an ongoingNCICGVHDnatural his-
tory protocol, with a median of 2845 pg/ml (range 92 to 17058), as
compared to 556 pg/ml (range 75 to 1834) in 18 normal donors.
Furthermore, in a subset of 22 patients in which severity of
CGVHD could be assessed by the presence of marked erythema
or sclerosis on 10 to 90% of their body surface areas (BSA), the
BAFF level correlated with the percentage of affected BSA (Spear-
man r51.63). We then explored the factors that might contribute
to elevated BAFF levels. In recipients recovering from either autol-
ogous or allogeneic transplant (without GVHD) we observed the
highest BAFF levels at day 0 (median of 10534 and 12240 pg/ml re-
spectively), when B cells were severely depleted. As B cell popula-
tions recovered to normal levels post transplant, plasma BAFF
concentrations declined (Spearman r 5 -.80 and r 5 -.60, respec-
tively), consistent with homeostatic cytokine-consumption dynam-
ics. Despite comparably high levels of BAFF (median of 11342 pg/
ml) at transplant day 0 in 16 patients who later developed CGHVD,
BAFF levels in the cross-sectional, natural history patient popula-
tion were only moderately correlated with the degree of post trans-
plant B cell recovery (r 5 -.48). Since inflammatory triggers caninduce elevated BAFF production by dendritic cells, we assessed
plasma levels of cytokines indicative of an inflammatory process.
In 34 patients, the plasma levels of IP-10 and sTNFRII correlated
positively with BAFF levels (r51.627 and r51.642, respectively),
consistent with active inflammatory processes in thoseCGVHDpa-
tients with elevated BAFF levels. In a multi-step regression model,
the levels of circulating B cells, plasma IP-10 and sTNFRII com-
bined to strongly predict BAFF levels (R 5 .834). These findings
suggest that both homeostatic recovery of B cell populations con-
suming BAFF and inflammatory cytokine cascades initiated by do-
nor-anti-host reactivity combine to regulate BAFF levels post
transplant.347
CORRELATION BETWEEN FOXP3 GENE POLYMORPHISMS IN DONORS,
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Introduction: Acute Graft-versus-host disease (aGVHD) is
a major complication of allogeneic stem cell transplantation (al-
loSCT). Risk factors include patient age, sex matching, CMV status
and degree of match. Regulatory T cells are critical for immune tol-
erance processes such as aGVHD, and express the transcription fac-
tor FOXP3, a member of the forkhead/winged-helix family,
identified as a key regulatory gene required for the development
and activity of these cells. It has been suggested that genetic expres-
sion of FOXP3 is inversely correlated with the severity of the
GVHD. We studied donors DNA looking for 5 polymorphisms
on the promoter region of the FOXP3 gene, and we tried to corre-
late them with presence and degree of aGVHD. Patients and
Methods: We studied donors of stem cells for allogeneic stem
cell transplants. We looked for the presence of the following poly-
morphisms by PCR: POL01–5906 T/A rs2869211; POL03–3279
A/C rs3761548; POL04–2383 C/T rs3761549; POL05–1383 C/T
rs2232364; POL06–924 A/G rs2232365.Results:Our sample con-
sisted of 31 donors, all siblings. In them we found only 2 of the 5
FOXP3 polymorphisms, either as homozygous or heterozygous.
These polymorphisms were found in 15/31 donors, with 12 being
homozygous (38.7%), and 3 heterozygous (9.7%). These genes
polymorphisms were POL03 y POL06. The most observed poly-
morphism was POL-06 with 9 cases, while POL-03 was found in
6 donors. Only sex difference and CMV status had an elevated haz-
ard ratio for developing GVHD (HR5 1.18, CI95%: 0.18 to 7.64;
p 5 0.85) and (HR 5 3.0, CI95%: 0.07 to 126; p 5 0.46) respec-
tively. We found no statistically significant difference in the inci-
dence of GVHD between patients who had received cells from
donor with or without a FOXP3 polymorphism (p 5 0.87). When
we analyzed the risk of presenting GVHD, results suggest that hav-
ing one of the 2 positive polymorphisms of the FOXP3 gene could
have a protective effect for the patient. For POL03 HR 5 0.87,
CI95%:0.18 to 4.14; p 5 0.86, and for POL06, HR 5 1, CI95%:
0.37 to 2.64, p5 0.67.Conclusions:Even though our sample is still
small to make conclusive remarks, we believe that our results point
toward some level of protection from acute GVHD in patients re-
ceiving cells from donors expressing POL03 and POL06. It is
also worthwhile mentioning the relatively high frequency of these
polymorphisms, as well as the absence of the other 3.348
HUMAN NEUTROPHIL ELASTASE STIMULATING CD41 AND CD81 T
CELLS IS A POTENTIAL PROTEIN VACCINE FOR LEUKEMIA PATIENTS
WITH DIVERSE HLA TYPES
Le, Q., Melenhorst, J.J., Hensel, N., Eniafe, R., Barrett, A.J. National
Heart, Lung and Blood Institute, NIH, Bethesda, MD.
128 Poster Session IIThe detection of naturally occurring T cells responding to pro-
teins overexpressed in myeloid leukemia suggests that vaccines
could boost the immune response to leukemia and achieve disease
control. Human neutrophil elastase (HNE) is a myeloid-restricted
protein highly expressed in myeloid leukemia cells. HNE protein
can induce both CD41 and CD81 T cell responses in healthy in-
dividuals including HLA-A*0201 negative individuals. To develop
HNE protein vaccine, and to identify major histocompatibility
complex (MHC) class II restricted or HLA-A*0201 negative
MHC class I restricted epitopes in HNE, we stimulated peripherial
blood mononuclear cells (PBMC) from 6 myeloid leukemia pre-
transplant patients with purified full length HNE protein. HNE
protein induced a response in CD41 and CD81T cells from 4 pa-
tients with acute myeloid leukemia (AML), as measured by IFN-g
protein expression in flow cytometric assay. However, no response
was detected in CD41 and CD81T cells from 2 pre-transplant pa-
tients with chronic myeloid leukemia (CML). Responses of CD41
and CD81 T cells to HNE protein stimulation were enhanced by
HNE expressing antigen-presenting T cells (T-APC), as measured
by flow cytometric assay. HNE protein induced significant IFN-g
expression in CD41 and CD81 T cells at 540X and 10X above
background in an (HLA-A11, 31) AML patient (patient #1), and
at 6X and 3.5X above background in an (HLA-A*0205, 03*) AML
patient (patient #2), as measured by quantitative Real-Time RT-
PCR assay (QRT-PCR). HNE protein also induced significant
IL-2 production in CD41 and CD81 T cells at 7.7X and 6.1X
above background in patient #1. Finally, we showed by QRT-
PCR that the T cell responses to HNE protein stimulation were
associated with the levels of HNE gene transcripts in the PBMC.
Further inverstigation of the correlation betweenHNEprotein spe-
cific CD41 and CD81T-cell responses and HNE gene transcripts
in consecutive samples obtained pre- and post-SCT may define an
ideal timewindow to vaccinate post-SCTpatients withmyeloid leu-
kemias. We found that full-length HNE protein stimulated both
CD41 and CD81 T cell responses in HLA-A*0201 negative pa-
tients with AML in the first three months following SCT. These re-
sults provide the rationale for using HNE protein to vaccinate
patients with myeloid leukemias after SCT to improve graft-ver-
sus-leukemia effects.349
ETHYLENECARBODIIMIDE (ECDI) COUPLED ALLOGENEIC ANTIGEN
PRESENTING CELLS INDUCE HUMAN CD41 REGULATORY T CELLS
Magg, T.1, Yu, X.-Z.2, Albert, M.H.1. 1 Dr. von Haunersches Kinderspi-
tal der LMU, Munich, Germany; 2 H. Lee Moffitt Cancer Center and Re-
search Institute, Tampa, FL.
Adoptive transfer of polyclonal CD41CD251 regulatory T cells
(nTregs) can tolerize transplantation alloresponses and prevent le-
thal acute graft-versus-host disease (GVHD) in mice. However iso-
lation of human CD41CD251 nTregs for adoptive
immunotherapy in sufficient numbers is cumbersome and prone
to contamination with non-regulatory, alloreactive CD251 T-
cells. Incubation of ethylenecarbodiimide (ECDI)-coupled antigen
presenting cells (APC) with naı¨ve T-cells and antigen has been
shown to induce tolerance in various experimental models.
We have therefore hypothesized that ECDI-coupled APC would
be able to tolerize alloreactive naı¨ve human CD41 T-cells from
HLA-incompatible human donors, and have tested whether this
would induce a Treg-like CD41 population (ECDI-Tregs). We
further investigated whether these cells could be expanded ex vivo
without loss of their regulatory capacity.
After 5 days of culture, ECDI-Tregs were as potent as freshly iso-
lated nTregs to suppress proliferation of effector T-cells in a mixed
lymphocyte reaction with allo-APC from the original APC donor
and they maintained high expression of CD62L and CD27 as well
as low CD127 expression. Foxp3 mRNA levels and Foxp3 protein
expression was significantly increased in ECDI-Tregs compared
to cells culturedwith untreated APC or freshly isolatedCD41 cells,
indicating either de novo induction or preferential expansion of
Tregs. ECDI treatment of APC resulted in increased apoptosis
and downregulation of costimulatory molecules CD40, CD80 and
CD86 while HLA-DR expression remained unchanged compared
to untreated cells. This might implicate T-cell receptor - MHC in-teraction without proper costimulation as a possible mechanism for
ECDI-Tregs induction. Addition of IL-2 and rapamycin and
weekly re-stimulation with untreated allo-APC led to exponential
expansion of ECDI-Tregs with increasing foxp3 levels and without
loss of their suppressive activity after 28 days.
These findings provide a proof of principle that ECDI-coupled
allo-APC can induce a potent regulatory T-cell population that
can be expanded ex vivo. These inducible Tregs suggests a novel ap-
proach to enhance the feasibility and effectiveness of inducing toler-
ance by Tregs as an adoptive immunotherapy in transplantation.350
MACROPHAGE MIGRATION INHIBITORY FACTOR AS A NEW TARGET IN
GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANS-
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Chang, Y.-Y.1, Miklos, S.1, Mueller, G.1, Holler, E.1, Lindner, P.2,
Leng, L.3, Schubert, T.4, Bucala, R.3, Hildebrandt, G.C.1. 1 University
of Regensburg Medical Center, Regensburg, Germany; 2 University of Re-
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Acute graft versus host disease (GVHD) is the major complica-
tion after allogeneic (allo) stem cell transplantation (SCT) involving
injury to host tissues by both inflammatory cytokines and donor-de-
rived cellular effectors. Macrophage migration inhibitory factor
(MIF) is produced by various cell types and has a broad range of
proinflammatory properties. We tested, whether MIF contributes
to GVHD by using a well established murine model. Lethally
(1300 cGy) irradiated B6D2F1 (H-2bxd) mice received SCT either
from syngeneic (syn) (B6D2F1) or allo (B6; H-2b) donors. One half
of animals after either syn or allo SCT were treated with polyclonal
antibodies against mouse MIF from day 0 until day 14, whereas the
other halves of syn and allo recipients received control IgG. GVHD
severity was assessed after SCTby survival and a clinical scoring sys-
tem assessing weight changes, fur texture, skin integrity, mobility
and posture. Syn recipients stayed clinically well and all animals sur-
vived regardless their treatment with control or anti-MIF. Animals
receiving allo-SCT plus control IgG developed significant aGVHD
and high mortality. By contrast, in allo anti-MIF treated recipients,
GVHD scores (day 21: 4.4 6 0.4 vs. 5.7 6 0.5) and weight loss
(24.6% vs. 45.4%) were reduced, and survival significantly im-
proved (p\0.05). In addition, target organ injury to the gut (histo-
pathology score: 4.3 6 0.7 vs. 8.0 6 2.6) as well as serum IFNg
(4397 6 995 vs. 6070 6 525 pg/ml) and TNFa (113.9 6 12.7 vs.
159.2 6 22.5 pg/ml) levels of anti-MIF treated allo recipients
were decreased by day 7 when compared to controls. Alloantigen-
specific T cell activation in vitro was significantly suppressed in
the presence of anti-MIF, as determined by a reduction in T cell
proliferation, IFNg and TNFa secretion.
We next challenged syn and allo recipients with P815 lympho-
blast-like mastocytoma cells (H-2d) at the time of transplantation
to asses the effect of anti-MIF on graft versus leukemia (GVL) re-
sponses. Significant P815 cell infiltration was seen after syn SCT
as demonstrated by FACS analysis of the spleens (67.2% infiltra-
tion) and by histopathology of the liver between day 14 and day
21 after SCT. In contrast, P815 cells were significantly cleared in
allo recipients treated with either control or anti-MIF (0.81% and
12.1% infiltration).
In summary, our data show an important role for MIF in GVHD
pathophysiology and suggest MIF as a promising target in reducing
GVHD without the loss of GVL.351
CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) FOLLOWING SIB-
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